<DOC>
	<DOCNO>NCT00336479</DOCNO>
	<brief_summary>Study effectiveness telaprevir ( VX-950 ) combination Pegylated Interferon Alfa 2a ( Peg-IFN-alfa-2a ) Ribavirin ( RBV ) reduce plasma hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) level</brief_summary>
	<brief_title>Phase 2 Study VX-950 , Pegasys® , Copegus® Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Hepatitis C virus Genotype 1 detectable plasma hepatitis C virus RNA Have infect hepatitis C virus great ( &gt; ) 6 month Seronegative hepatitis B surface antigen Human Immunodeficiency Virus 1 2 Must agree use 2 method contraception , include 1 barrier method , 24 week completion study ( unless subject female document nonchildbearing potential ) Female subject must negative pregnancy test visit first dose Received approve investigational drug drug regimen treatment hepatitis C Any medical contraindication Pegylated Interferon Alfa 2a Ribavirin therapy Any cause significant liver disease addition hepatitis C ; may include limited , hepatitis B , drug alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , Nonalcoholic Steatohepatitis primary biliary cirrhosis Diagnosed suspected hepatocellular carcinoma Histologic evidence hepatic cirrhosis ( include compensate cirrhosis ) base liver biopsy take within 2 year study start Alcohol abuse excessive use last 12 month Participation investigational drug study within 90 day drug administration participation 2 drug study last 12 month ( exclusive current study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>